본문으로 건너뛰기
← 뒤로

Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer.

1/5 보강
Journal of mammary gland biology and neoplasia 2026 Vol.31(1)
Retraction 확인
출처

Han D, Xu J, Guo C

📝 환자 설명용 한 줄

Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Han D, Xu J, Guo C (2026). Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer.. Journal of mammary gland biology and neoplasia, 31(1). https://doi.org/10.1007/s10911-026-09600-3
MLA Han D, et al.. "Synergistic Anticancer Effects of Apatinib and PD-L1 Inhibition in Breast Cancer.." Journal of mammary gland biology and neoplasia, vol. 31, no. 1, 2026.
PMID 41619044

Abstract

Studies in breast cancer have demonstrated that apatinib exhibits both antiangiogenic and antitumor effects, while PD-L1 inhibitors have similarly shown meaningful clinical benefit. Building upon these observations, this study evaluated the potential synergistic antitumor effects of combining apatinib with a PD-L1 inhibitor and examined the mechanistic basis for their interaction in breast cancer. Notably, we found that this regimen could significantly suppress the proliferation, migration, and invasion of MCF-7 and MDA-MB-231 cells, and promote cell apoptosis. In addition, the levels of p-ERK, NF-κB, and Slug were markedly reduced in vitro. Collectively, these findings support the potential clinical utility of combining apatinib and PD-L1 inhibition, as evidenced by consistent in vitro and in vivo synergy.

MeSH Terms

Humans; Female; Pyridines; Breast Neoplasms; Drug Synergism; Cell Proliferation; Animals; Apoptosis; Cell Movement; B7-H1 Antigen; Xenograft Model Antitumor Assays; Mice; Cell Line, Tumor; MCF-7 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols

같은 제1저자의 인용 많은 논문 (5)